EKSO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Ekso Bionics Holdings Inc (EKSO) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock shows mixed signals with no significant positive catalysts, weak financial performance, and no proprietary trading signals. While the technical indicators are somewhat neutral to bearish, the lack of strong growth or momentum makes it prudent to hold off on purchasing this stock right now.
The MACD is negatively expanding, indicating bearish momentum. RSI is neutral at 45.118, suggesting no clear overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading below the pivot level of 9.467, with key support at 8.457 and resistance at 10.478. Overall, the technical outlook is mixed.
Gross margin improved by 12.71% YoY to 60.3%. Analysts from H.C. Wainwright raised the price target from $4 to $6 and maintained a Buy rating, citing sales recovery.
Net income dropped by 31.42% YoY, and EPS declined by 64.71% YoY in Q3 2025, reflecting weak profitability. The regular market price dropped by 7.16%, and there is no recent news or significant trading activity from hedge funds, insiders, or Congress. The stock has a 60% chance of declining by 13.56% in the next month based on historical patterns.
In Q3 2025, revenue increased slightly by 2.37% YoY to $4.23M. However, net income dropped significantly by 31.42% YoY to -$1.42M, and EPS fell by 64.71% YoY to -0.54. Gross margin improved to 60.3%, up 12.71% YoY, but the overall financial performance remains weak.
H.C. Wainwright raised the price target from $4 to $6 and maintained a Buy rating. However, they noted that the sales recovery in Q3 might be idiosyncratic, and the sustainability of this trend remains uncertain.
